Search Icon

IEDA aids startup developing metastatic melanoma cure

May 16, 2016

May is Melanoma/Skin Cancer Detection and Prevention Month, so it’s a fitting time to talk about an exciting Iowa startup developing a cure for the worst form of the disease. Viewpoint Molecular Targeting operates out of the University of Iowa Research Park, and uses technology originally developed at the university to diagnose and eventually cure metastatic melanoma, a disease that will kill more than 10,000 Americans this year.

The company’s lead product determines the location and extent of cancerous tumors in the body, and then can be used to direct a lethal dose of radiation precisely into those affected cells. It’s a promising approach, and the company has attracted state and federal funds to help further its work in Iowa.

In March 2015, the Iowa Economic Development Authority (IEDA) awarded Viewpoint a Demonstration Fund loan. Since that time the U.S. government has awarded the company four Small Business Innovation Research (SBIR) grants and the Iowa Innovation Corporation has also awarded a grant to the company.

Most recently, the Iowa Biotechnology Association awarded Viewpoint its top prize at this year’s Partnering for Growth Biotech Innovation Showcase, besting 11 competitors. As part of its mission, IEDA helps startups like Viewpoint commercialize technology developed at Iowa’s universities and employ Iowans. To learn about Iowa’s commitment to fostering innovation, contact



See how we stack up

The 50-State Comparison Tool

Stay Informed.
Sign Up to Receive Updates.
Emails highlighting economic development news, program updates and upcoming events.